<html><head><link rel="stylesheet" type="text/css" href="css/style.css"></head><body><div id="main"><h1>Scignal</h1></div> <div class="container"><div class="row"><div class="search"><h2>All Results for : "Checkpoint inhibitor" and "resistance"</a></h2></div><table><tr><td class="head"><h3>BioRxiv</h3></td><td class="head"><h3>PubMed</h3></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Combining radiomics and mathematical modeling to elucidate mechanisms of resistance to immune checkpoint blockade in non-small cell lung cancer</h4><p><a href="https://www.biorxiv.org/content/10.1101/190561v1">Link</a></p><p><b>Date:</b> 2017-09-22</p><p><b>Authors:</b> Daryoush Saeed-Vafa ... Jill A. Gallaher</p><p><b>Downloads:</b> 776</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Immune therapies have shown promise in a number of cancers, and clinical trials using the anti-PD-L1/PD-1 checkpoint inhibitor in lung cancer have been successful for a number of patients.  However, some patients either do not respond to the treatment or have cancer recurrence after an initial response.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Endothelial sphingosine 1-phosphate receptors promote vascular normalization and antitumor therapy.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/31988136">Link</a></p><p><b>Date:</b> 2020-01-28</p><p><b>Authors:</b> Andreane Cartier ...  Timothy Hla</p><p><b>Journal:</b> Proc. Natl. Acad. Sci. U.S.A.</p><p><b>IF (7 or above):</b> 9.35</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Sphingosine 1-phosphate receptor-1 (S1PR1) is essential for embryonic vascular development and maturation.  In the adult, it is a key regulator of vascular barrier function and inflammatory processes.</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor resistant HER2-positive breast cancer</h4><p><a href="https://www.biorxiv.org/content/10.1101/671198v2">Link</a></p><p><b>Date:</b> 2019-06-14</p><p><b>Authors:</b> Qingfei Wang ... Siyuan Zhang</p><p><b>Downloads:</b> 601</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Development of acquired resistance to targeted cancer therapy is one of the most significant clinical challenges.  Acquiring resistance under drug selection pressure is a result of evolutionary adaptation to a complex and dynamic tumor microenvironment (TME).</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32061257">Link</a></p><p><b>Date:</b> 2020-02-17</p><p><b>Authors:</b> Jia-Qiao Fan ...  Jianxun Song</p><p><b>Journal:</b> Mol. Cancer</p><p><b>IF (7 or above):</b> 11.35</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Pancreatic ductal adenocarcinoma (PDAC) is an incurable cancer resistant to traditional treatments, although a limited number of early-stage patients can undergo radical resection.  Immunotherapies for the treatment of haematological malignancies as well as solid tumours have been substantially impr ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Tankyrase inhibition sensitizes melanoma to PD-1 immune checkpoint blockade in syngeneic mouse models</h4><p><a href="https://www.biorxiv.org/content/10.1101/526343v1">Link</a></p><p><b>Date:</b> 2019-01-22</p><p><b>Authors:</b> Jo Waaler ... Stefan Krauss</p><p><b>Downloads:</b> 569</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> The development of immune checkpoint inhibitors represents a major breakthrough in cancer therapy.  Nevertheless, a substantial number of patients fail to respond to checkpoint pathway blockade.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/31355495">Link</a></p><p><b>Date:</b> 2019-07-29</p><p><b>Authors:</b> Smita S Chandran ...  Christopher A Klebanoff</p><p><b>Journal:</b> Immunol. Rev.</p><p><b>IF (7 or above):</b> 10.85</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Adoptive cell transfer (ACT) using chimeric antigen receptor (CAR)-modified T cells can induce durable remissions in patients with refractory B-lymphoid cancers.  By contrast, results applying CAR-modified T cells to solid malignancies have been comparatively modest.</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Understanding inhibitor resistance in Mps1 kinase through novel biophysical assays and structures</h4><p><a href="https://www.biorxiv.org/content/10.1101/112086v2">Link</a></p><p><b>Date:</b> 2017-02-27</p><p><b>Authors:</b> Yoshitaka Hiruma ... Anastassis Perrakis</p><p><b>Downloads:</b> 446</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Monopolar spindle 1 (Mps1/TTK) is a protein kinase essential in mitotic checkpoint signalling, preventing anaphase until all chromosomes are properly attached to spindle microtubules.  Mps1 has emerged as a potential target for cancer therapy, and a variety of compounds have been developed to inhibit its kinase activity.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: A novel role for the HLH protein Inhibitor of Differentiation 4 (ID4) in the DNA damage response in basal-like breast cancer.</h4><p><a href="https://www.biorxiv.org/content/10.1101/281196v1">Link</a></p><p><b>Date:</b> 2018-03-14</p><p><b>Authors:</b> Laura A Baker ... Alexander Swarbrick</p><p><b>Downloads:</b> 344</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Basal-like breast cancer (BLBC) is a poorly characterised, heterogeneous disease.  Patients are diagnosed with aggressive, high-grade tumours and often relapse with chemotherapy resistance.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: The novel reversible LSD1 inhibitor SP-2577 promotes anti-tumor immunity in SWItch/Sucrose-NonFermentable (SWI/SNF) complex mutated ovarian cancer</h4><p><a href="https://www.biorxiv.org/content/10.1101/2020.01.10.902528v2">Link</a></p><p><b>Date:</b> 2020-01-11</p><p><b>Authors:</b> Raffaella Soldi ... Sunil Sharma</p><p><b>Downloads:</b> 315</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Chromatin remodeling SWItch/Sucrose-NonFermentable (SWI/SNF) complexes, initially identified in yeast 20 years ago, are evolutionarily conserved multi-subunit protein complexes that use the energy from hydrolysis of adenosine triphosphate (ATP) to remodel nucleosome structure and modulate transcription.  Mutations in proteins of SWI/SNF complexes occur in 20% of human cancers including ovarian cancer (OC).</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Inhibitor of the spindle assembly checkpoint surpasses apoptosis sensitizer in synergy with taxanes</h4><p><a href="https://www.biorxiv.org/content/10.1101/414359v1">Link</a></p><p><b>Date:</b> 2018-09-11</p><p><b>Authors:</b> Teng-Long Han ... Hang Sha</p><p><b>Downloads:</b> 260</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> The antitumor effect of taxanes have been attributed to their ability to induce mitotic arrest through activation of the spindle assembly checkpoint.  Cell death following prolonged mitotic arrest is mediated by the intrinsic apoptosis pathway.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Therapeutically actionable PAK4 is amplified, overexpressed and involved in bladder cancer progression</h4><p><a href="https://www.biorxiv.org/content/10.1101/740316v1">Link</a></p><p><b>Date:</b> 2019-08-20</p><p><b>Authors:</b> Darshan S Chandrashekar ... Guru Sonpavde</p><p><b>Downloads:</b> 173</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Muscle-invasive bladder carcinomas (MIBCs) are aggressive genitourinary malignancies.  Disease incidence and survival rates vary based on aggressiveness and treatment options.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: RIPK3 inhibition prevents KRAS mutant p53 deficient lung tumor progression by impeding MDSCs</h4><p><a href="https://www.biorxiv.org/content/10.1101/853978v1">Link</a></p><p><b>Date:</b> 2019-11-25</p><p><b>Authors:</b> Asha Jayakumar</p><p><b>Downloads:</b> 91</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> KRAS mutant p53 deficient (KP) non-small cell lung carcinoma (NSCLC) lacks targeted therapies.  Existing treatments for lung cancer cause resistance and result in toxicities requiring novel effective therapies.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: CAR T cells for solid tumors: genome-wide dysfunction signature confirms value of c-Jun overexpression, but signals heterogeneity</h4><p><a href="https://www.biorxiv.org/content/10.1101/2020.02.07.939033v1">Link</a></p><p><b>Date:</b> 2020-02-11</p><p><b>Authors:</b> Mostapha Benhenda</p><p><b>Downloads:</b> 91</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Chimeric antigen receptor (CAR) T cells still have limited effects in cancer, and especially in solid tumors, due to T cell dysfunction and exhaustion.  CAR T cells overexpressing c-Jun (JUN CAR T cells) have been introduced to solve this problem.</p></div></td></div><td></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Suppression of Docetaxel induced apoptosis in Survivin-depleted cells due to failure of sustained mitotic block</h4><p><a href="https://www.biorxiv.org/content/10.1101/834259v1">Link</a></p><p><b>Date:</b> 2019-11-07</p><p><b>Authors:</b> Teng-Long Han ... Zhi-Xin Jiang</p><p><b>Downloads:</b> 68</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> The antitumor effect of taxanes have been attributed to their ability to induce mitotic arrest through activation of the spindle assembly checkpoint.  Cell death following prolonged mitotic arrest is mediated by the intrinsic apoptosis pathway.</p></div></td></div><td></td></tr></table></div><hr></div></body></html>